SEngine Precision Medicine, Inc.

SEngine Precision Medicine, Inc. is a biotechnology firm focused on delivering personalized cancer treatment solutions through innovative testing technologies, particularly its flagship PARIS® Test, enhancing therapeutic decisions for oncologists and patients. SEngine Precision Medicine, Inc. specializes in personalized cancer treatment solutions and was founded in 2015 in Seattle, US.

The company has received Series A funding totaling USD 10. 00 mn, led by WRF Capital, with notable participation from Alethea Capital Management and Vincere Capital Biotech LLC. The founder, Tom Neary, has experience in the biotech sector, establishing a firm committed to advancing cancer care. The company has been involved in 3 deals, with its most recent funding round taking place on July 28, 2022.

SEngine Precision Medicine specializes in personalized cancer treatment solutions through its flagship product, the PARIS® Test. This CLIA-certified platform evaluates patients’ tumor samples using a customized panel of up to 42 oncology drugs selected from a library of approximately 200 curated and validated treatments. Designed to provide actionable insights, the PARIS® Test serves oncologists by identifying potentially effective therapies for individual patients, including FDA-approved targeted therapies, chemotherapies, and investigational drugs under clinical trials. The primary end users of this service are oncologists, cancer patients, and healthcare institutions seeking advanced and tailored treatment options.

While the company is based in Bothell, Washington, its services are available to clients across the United States, catering to a diverse array of cancer patients seeking innovative therapeutic approaches. SEngine Precision Medicine generates revenue through the provision of its PARIS® Test, which is offered directly to healthcare providers and oncologists. The transaction structure is primarily B2B, with the lab providing actionable reports to medical professionals following the analysis of patient samples. Revenue is derived from fees associated with each test conducted, reflecting the personalized nature of the service.

The pricing structure is designed to accommodate healthcare providers, ensuring that they can access the test for their patients efficiently. These transactions typically involve direct billing to healthcare institutions or partnerships with medical practices, facilitating a streamlined process for delivering personalized cancer care solutions. In July 2022, SEngine Precision Medicine, Inc. raised USD 10.

00 mn in Series A funding, led by WRF Capital, to support its ongoing initiatives in drug discovery and clinical validation of the PARIS Test platform. The company plans to utilize this funding to hire additional team members and expand its lab space, which is crucial for fostering biopharmaceutical and pharmaceutical partnerships. There are ongoing efforts to explore new markets and geographic regions for expansion, although specific targets have not been disclosed.